Syndax Pharmaceuticals will be hosting a study dinner for ECOG-ACRIN study E2112, A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Men and Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer, on July 15, 2015 at the Crowne Plaza, in downtown Denver. A presentation on this Phase III trial including background on entinostat, an Histone Deacetylase Inhibitor (HDACi), and the scientific rationale for the trial will be provided. Dr. Roisin Connolly, the Study Chair from Johns Hopkins University, and Syndax will provide the study overview, an update on the study progress and will hold a Q & A session. R.S.V.P to E2112-Dinner@ecog-acrin.org<mailto:E2112-Dinner@ecog-acrin.org> by July 10th. If you have any questions, don't hesitate to contact me. E2112 investigators, nurses and coordinators are invited.
For information contact: Alison Bricker, ECOG-ACRIN Project Management, abricker@ecogchair.org<mailto:abricker@ecogchair.org>
Date: July 15, 2015
Time: 6:30-8:30pm
Location: Crowne Plaza, Denver Downtown, 1450 Glenarm Place, Denver, CO 80202
E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Men and Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer https://clinicaltrials.gov/ct2/show/NCT02115282
